Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Fulcrum Therapeutics, Inc. (FULC)
NASDAQHealth CareBiotechnologySnapshot 2026-10-23
$3.680.00%
Close 2026-10-23 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|---|---|
| Quarter ending 2026-12-30 | ||
| Revenue | — | 0 |
| EPS | — | -0.051 |
| Annual ending 2026-12-31 | ||
| Revenue | — | 311,890 |
| EPS | — | -0.603 |
| Annual ending 2027-12-31 | ||
| Revenue | — | 361.24M |
| EPS | — | |
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
maintain cash and equivalents near $350 million | It has about $352 million in cash to support operations. | Intact | cash falls below $300 million by end 2026 | Cash and cash equivalents: $48.466M FY2026-Q2; GAAP. Published target: >= $350 million cash and equivalents. Target period is not explicitly aligned with this observation. Source date unavailable48,466,000 USD · source valueSource reportLast status assessment Oct 25, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_balance_sheet. Reference: 2026-Q2. Source status: unverified. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 4, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making biotechnology company rather than an established compounder. The long-term thesis is in a watch state: management has shifted from developing pociredir to reviewing strategic alternatives, while cutting its workforce sharply to preserve capital.
FULC is described as cheap versus peers, but the valuation model has low confidence and the expectations gap is negative. The priced-in assessment is tagged justified, with no fragility gates fired; that does not remove the risks tied to losses and weak performance.
Near term, earnings-miss risk is elevated, and a guidance cut would add a meaningful concern. Over the multi-year view, the workforce reduction may lower costs, while management expects cash to fund operations into 2029; however, pociredir’s discontinuation and the strategic review leave the business direction uncertain.
A key swing factor is whether the strategic review leads to a viable path after FDA concerns ended pociredir development. A guidance cut or further weakening jobs data would add pressure, while continued strength among healthcare bellwethers could support the sector backdrop.
The 1-to-3-year view is uncertain: cost control and runway provide time, but weak performance, management volatility, and the unresolved strategic review keep risk elevated. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management figures unavailable.
Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
complete comprehensive review of strategic alternatives | A primary condition in Fulcrum Therapeutics, Inc.'s published investment case. The stated target is engage and progress in strategic alternatives review. | Recovered | no meaningful progress in strategic alternatives review by mid 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 25, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
reduce workforce by approximately 85% | A primary condition in Fulcrum Therapeutics, Inc.'s published investment case. The stated target is reduce workforce by ~85%. | Intact | workforce reduction falls short of ~85% by mid 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 25, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.67 → $-0.12 · observed estimates
$0.36B → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.67 | $361,240,000 | 6 / 6 |
| 2026-07-25 | $-0.58 | $0 | 7 / 6 |
| 2026-07-26 | $-0.58 | $0 | 7 / 6 |
| 2026-07-27 | $-0.67 | $361,240,000 | 6 / 6 |
| 2026-07-28 | $-0.67 | $361,240,000 | 6 / 6 |
| 2026-07-29 | $-0.58 | $0 | 7 / 6 |
| 2026-07-30 | $-0.67 | $361,240,000 | 6 / 6 |
| 2026-07-31 | $-0.58 | $0 | 7 / 6 |
| 2026-08-01 | $-0.67 | $361,240,000 | 6 / 6 |
| 2026-08-02 | $-0.58 | $0 | 7 / 6 |
| 2026-08-03 | $-0.58 | $0 | 7 / 6 |
| 2026-08-04 | $-0.58 | $0 | 7 / 6 |
| 2026-08-05 | $-0.53 | $0 | 7 / 5 |
| 2026-08-06 | $-0.53 | $0 | 7 / 5 |
| 2026-08-07 | $-0.62 | $361,240,000 | 6 / 6 |
| 2026-08-08 | $-0.53 | $0 | 7 / 5 |
| 2026-08-09 | $-0.53 | $0 | 7 / 5 |
| 2026-08-10 | $-0.53 | $0 | 7 / 5 |
| 2026-08-12 | $-0.49 | $0 | 7 / 5 |
| 2026-08-13 | $-0.49 | $0 | 7 / 5 |
| 2026-08-14 | $-0.62 | $361,240,000 | 6 / 6 |
| 2026-08-15 | $-0.62 | $361,240,000 | 6 / 6 |
| 2026-08-16 | $-0.62 | $361,240,000 | 6 / 6 |
| 2026-08-17 | $-0.62 | $361,240,000 | 6 / 6 |
| 2026-08-18 | $-0.62 | $361,240,000 | 6 / 6 |
| 2026-08-19 | $-0.62 | $361,240,000 | 6 / 6 |
| 2026-08-20 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-21 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-22 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-23 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-24 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-25 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-26 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-27 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-28 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-29 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-30 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-31 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-01 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-02 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-03 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-04 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-05 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-06 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-07 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-08 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-09 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-10 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-11 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-12 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-13 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-14 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-15 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-16 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-17 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-18 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-19 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-20 | $-0.12 | Unavailable | 5 / 4 |
| 2026-09-21 | $-0.12 | Unavailable | 5 / 4 |
| 2026-09-22 | $-0.12 | Unavailable | 5 / 4 |
| 2026-09-23 | $-0.12 | Unavailable | 5 / 4 |
| 2026-09-24 | $-0.12 | Unavailable | 5 / 4 |
| 2026-09-25 | $-0.12 | Unavailable | 5 / 4 |
| 2026-09-26 | $-0.12 | Unavailable | 5 / 4 |
| 2026-09-27 | $-0.12 | Unavailable | 5 / 4 |
| 2026-09-28 | $-0.12 | Unavailable | 5 / 4 |
| 2026-09-29 | $-0.12 | Unavailable | 5 / 4 |
| 2026-09-30 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-01 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-02 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-03 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-04 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-05 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-06 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-07 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-08 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-09 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-10 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-11 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-12 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-13 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-14 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-15 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-16 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-17 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-18 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-19 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-20 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-21 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-22 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-23 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-24 | $-0.12 | Unavailable | 5 / 4 |
| 2026-10-25 | $-0.12 | Unavailable | 5 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 4 Hold · 1 Sell / Strong Sell
Recent actions · Sep 26–Oct 25 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 26, 2026–Oct 25, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.